JP2010506147A - 関節リウマチを有する患者のための疾患進行のリスク評価 - Google Patents

関節リウマチを有する患者のための疾患進行のリスク評価 Download PDF

Info

Publication number
JP2010506147A
JP2010506147A JP2009529589A JP2009529589A JP2010506147A JP 2010506147 A JP2010506147 A JP 2010506147A JP 2009529589 A JP2009529589 A JP 2009529589A JP 2009529589 A JP2009529589 A JP 2009529589A JP 2010506147 A JP2010506147 A JP 2010506147A
Authority
JP
Japan
Prior art keywords
markers
patients
score
disease progression
crp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009529589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506147A5 (enExample
Inventor
カール，ヨハン
グルネルト，ファイト
ロリンガー，ウォルフガング
ヴィルト，ノルベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2010506147A publication Critical patent/JP2010506147A/ja
Publication of JP2010506147A5 publication Critical patent/JP2010506147A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009529589A 2006-09-29 2007-09-25 関節リウマチを有する患者のための疾患進行のリスク評価 Pending JP2010506147A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06020645 2006-09-29
EP06021887 2006-10-19
PCT/EP2007/008313 WO2008037420A1 (en) 2006-09-29 2007-09-25 Assessing the risk of disease progression for a patient with rheumatoid arthritis

Publications (2)

Publication Number Publication Date
JP2010506147A true JP2010506147A (ja) 2010-02-25
JP2010506147A5 JP2010506147A5 (enExample) 2010-07-15

Family

ID=38859738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009529589A Pending JP2010506147A (ja) 2006-09-29 2007-09-25 関節リウマチを有する患者のための疾患進行のリスク評価

Country Status (6)

Country Link
US (1) US8058013B2 (enExample)
EP (1) EP2074428B1 (enExample)
JP (1) JP2010506147A (enExample)
CA (1) CA2663730A1 (enExample)
ES (1) ES2545688T3 (enExample)
WO (1) WO2008037420A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012103238A (ja) * 2010-10-14 2012-05-31 Nagasaki Univ 免疫複合体の網羅的解析方法および新規関節リウマチバイオマーカー
JP2013508687A (ja) * 2009-10-15 2013-03-07 クレッシェンド バイオサイエンス インコーポレイテッド 炎症性疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法
US10718765B2 (en) 2014-04-02 2020-07-21 Crescendo Bioscience, Inc. Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
US10983120B2 (en) 2015-09-29 2021-04-20 Crescendo Bioscience Methods for assessing response to inflammatory disease therapy withdrawal
US11493512B2 (en) 2014-06-10 2022-11-08 Laboratory Corporation Of America Holdings Biomarkers and methods for measuring and monitoring axial spondyloarthritis activity
US11656227B2 (en) 2015-09-29 2023-05-23 Crescendo Bioscience Biomarkers and methods for assessing psoriatic arthritis disease activity

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038104A1 (en) * 2008-10-03 2010-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event.
US20130246097A1 (en) * 2010-03-17 2013-09-19 Howard M. Kenney Medical Information Systems and Medical Data Processing Methods
JP5786020B2 (ja) * 2010-04-16 2015-09-30 アボットジャパン株式会社 関節リウマチを診断する方法および試薬
WO2012012183A2 (en) 2010-06-30 2012-01-26 New York University Quantifying local inflammatory activity and its use to predict disease progression and tailor treatments
US20140142861A1 (en) * 2010-11-06 2014-05-22 Oklahoma Medical Research Foundation Biomarkers For Predicting Progressive Joint Damage
CN105229470B (zh) * 2013-03-15 2018-11-27 艾克斯肯诊断股份有限公司 用于治疗和诊断系统性红斑狼疮的方法
JP2015061592A (ja) * 2013-08-21 2015-04-02 コニカミノルタ株式会社 超音波診断装置、超音波画像処理方法およびコンピュータ読み取り可能な非一時的な記録媒体
GB201603571D0 (en) * 2016-03-01 2016-04-13 Univ Warwick Markers for skeletal disorders
US20220390466A1 (en) * 2019-10-30 2022-12-08 Cd Diagnostics, Inc. Biomarkers of early osteoarthritis
CN114089632B (zh) * 2021-11-15 2023-08-18 陕西师范大学 基于模糊逻辑的风湿免疫疾病特征识别方法及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085859A1 (en) * 2004-02-27 2005-09-15 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
WO2006098401A1 (ja) * 2005-03-16 2006-09-21 The University Of Tokushima 関節リウマチ罹患リスクの測定方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105893D0 (en) * 1991-03-20 1991-05-08 Orion Yhtymae Oy Bone resorption assay based on a peptide liberated during collagen degradation
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
ES2154739T3 (es) * 1994-10-17 2001-04-16 Osteometer Biotech As Estimacion del modelo de fragmentacion del colageno en fluidos corporales y el diagnostico de trastornos asociados con el metabolismo del colageno.
FR2752842B1 (fr) 1996-08-30 1998-11-06 Biomerieux Sa Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide
NL1004539C2 (nl) 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
EP1034186A2 (en) 1997-11-28 2000-09-13 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
FR2773157B1 (fr) 1997-12-30 2001-10-05 Bio Merieux Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide
NZ504683A (en) * 1998-01-09 2002-06-28 Pfizer Amide derivatives and pharmaceutical compositions thereof and their use as matrix metalloprotease inhibitors
ES2174770T1 (es) 1999-12-21 2002-11-16 Innogenetics Nv Peptidos diseñados para el diagnostico y el tratamiento de artritis reumatoide.
NL1019540C2 (nl) 2001-12-11 2003-07-01 Stichting Tech Wetenschapp Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit.
US20060063162A1 (en) * 2004-09-23 2006-03-23 Deng David X Biological marker for inflammation
MX2008002101A (es) * 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085859A1 (en) * 2004-02-27 2005-09-15 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
WO2006098401A1 (ja) * 2005-03-16 2006-09-21 The University Of Tokushima 関節リウマチ罹患リスクの測定方法

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508687A (ja) * 2009-10-15 2013-03-07 クレッシェンド バイオサイエンス インコーポレイテッド 炎症性疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法
US9200324B2 (en) 2009-10-15 2015-12-01 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
US11300575B2 (en) 2009-10-15 2022-04-12 Laboratory Corporation Of America Holdings Biomarkers and methods for measuring and monitoring inflammatory disease activity
JP2012103238A (ja) * 2010-10-14 2012-05-31 Nagasaki Univ 免疫複合体の網羅的解析方法および新規関節リウマチバイオマーカー
US10718765B2 (en) 2014-04-02 2020-07-21 Crescendo Bioscience, Inc. Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
US11493512B2 (en) 2014-06-10 2022-11-08 Laboratory Corporation Of America Holdings Biomarkers and methods for measuring and monitoring axial spondyloarthritis activity
US10983120B2 (en) 2015-09-29 2021-04-20 Crescendo Bioscience Methods for assessing response to inflammatory disease therapy withdrawal
US11656227B2 (en) 2015-09-29 2023-05-23 Crescendo Bioscience Biomarkers and methods for assessing psoriatic arthritis disease activity
US12385912B2 (en) 2015-09-29 2025-08-12 Laboratory Corporation Of America Holdings Methods of treatment of arthritic disorders

Also Published As

Publication number Publication date
WO2008037420A1 (en) 2008-04-03
US20090270272A1 (en) 2009-10-29
CA2663730A1 (en) 2008-04-03
ES2545688T3 (es) 2015-09-15
US8058013B2 (en) 2011-11-15
EP2074428A1 (en) 2009-07-01
EP2074428B1 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
US8058013B2 (en) Assessing risk of disease progression in rheumatoid arthritis patients
Visser Early diagnosis of rheumatoid arthritis
Yamanaka et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis
Hurnakova et al. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis
JP4495168B2 (ja) 抗ｃｃｐおよびインターロイキン６の測定による慢性関節リウマチの評価方法
US8062907B2 (en) Method to assess the severity of rheumatoid arthritis by measuring anti-CCP and serum amyloid A
CN101283278A (zh) 在类风湿性关节炎的诊断中的抗ccp和抗核抗体
Fex et al. Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet.
CN101523218B (zh) 评估类风湿性关节炎患者疾病进展的风险
JP4610605B2 (ja) リウマチ因子およびインターロイキン６の測定による慢性関節リウマチの評価方法
CN104105967B (zh) 生腱蛋白c及其在类风湿关节炎的用途
JP2018506720A (ja) 抗ｃｃｐおよび抗ｐｉｋ３ｃｄを測定することによる関節リウマの査定方法
HK1136628A (en) Assessing the risk of disease progression for a patient with rheumatoid arthritis
HK1136628B (en) Assessing the risk of disease progression for a patient with rheumatoid arthritis
Yasin et al. Extensive study of CCN4, VCAM-1, MMP-3, and GM-CSF as reliable markers for disease activity in rheumatoid arthritis
El Kosaier et al. Serum amyloid a level and musculoskeletal ultrasound in assessment of disease activity in rheumatoid arthritis patients
WO2012098256A1 (en) Anti-cd146 auto-antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110810

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120508